RESPONSE TO T-DM1 IN HER2-POSITIVE BREAST CANCER BRAIN METASTASES (BM)

被引：0
|
作者：
Berghoff, A. S. [1 ]
Bartsch, R. [1 ]
Bergen, E. [1 ]
Rudas, M. [2 ]
Gnant, M. [3 ]
Dieckmann, K. [4 ]
Pinker, K. [5 ]
Zielinski, C. C. [1 ]
Steger, G. G. [1 ]
Preusser, M. [1 ]
机构：
[1] Med Univ Vienna, Dept Med 1, Clin Div Oncol, Vienna, Austria
[2] Med Univ Vienna, Dept Pathol, Vienna, Austria
[3] Med Univ Vienna, Dept Surg, Vienna, Austria
[4] Med Univ Vienna, Dept Radiotherapy, Vienna, Austria
[5] Med Univ Vienna, Dept Radiol, Vienna, Austria
来源：
NEURO-ONCOLOGY | 2014年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P08.01
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Ado-trastuzumab emtansine (T-DM1) controls tumor progression of established HER2-positive breast cancer brain metastases in mice
    Ferraro, Gino B.
    Askoxylakis, Vasileios
    Kodack, David P.
    Badeaux, Mark
    Fukumura, Dai
    Engelman, Jeffrey A.
    Jain, Rakesh K.
    CANCER RESEARCH, 2016, 76
  • [32] Metastatic HER2-positive Breast Cancer New Perspectives with Trastuzumab Emtansine (T-DM1)
    Satzger, Ulla
    ONKOLOGIE, 2013, 36 (09): : 525 - 525
  • [33] Phase I/II study of T-DM1 alone versus T-DM1 and metronomic temozolomide in secondary prevention of HER2-Positive breast cancer brain metastases following stereotactic radiosurgery
    Zimmer, Alexandra S.
    Gril, Brunilde
    Steinberg, Seth
    Smart, DeeDee
    Gilbert, Mark
    Armstrong, Teri
    Xiao, Lin
    Houston, Nicole
    Biassou, Nadia
    Brastianos, Priscilla
    Carter, Scott
    Lyden, David C.
    Lipkowitz, Stanley
    Steeg, Patricia
    CANCER RESEARCH, 2018, 78 (04)
  • [34] Phase I/II study of T-DM1 alone versus T-DM1 and metronomic temozolomide in secondary prevention of HER2-positive breast cancer brain metastases following stereotactic radiosurgery.
    Zimmer, Alexandra Dos Santos
    Steinberg, Seth M.
    Smart, DeeDee Kay
    Gilbert, Mark R.
    Armstrong, Terri
    Burton, Eric
    Houston, Nicole D.
    Biassou, Nadia
    Gril, Brunilde
    Brastianos, Priscilla Kaliopi
    Carter, Scott L.
    Lyden, David
    Lipkowitz, Stanley
    Steeg, Patricia Schriver
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [35] Brain metastases in HER2-positive breast cancer
    Lin, Nancy U.
    LANCET ONCOLOGY, 2013, 14 (03): : 185 - 186
  • [36] Enhanced antitumor efficacy of T-DM1 in combination with pertuzumab in HER2-positive breast cancer models
    Sun, Yuliang
    Dey, Nandini
    Carlson, Jennifer
    Brammer, Melissa
    De, Pradip
    Leyland-Jones, Brian
    CANCER RESEARCH, 2014, 74 (19)
  • [37] Adverse Events of Trastuzumab Emtansine (T-DM1) in the Treatment of HER2-Positive Breast Cancer Patients
    Kowalczyk, Lidia
    Bartsch, Rupert
    Singer, Christian F.
    Farr, Alex
    BREAST CARE, 2017, 12 (06) : 401 - 408
  • [38] Risk of radionecrosis in HER2-positive breast cancer with brain metastasis receiving trastuzumab emtansine (T-DM1) and brain stereotactic radiosurgery
    Chun, Seok-Joo
    Kim, Kyubo
    Kim, Yong Bae
    Paek, Sun Ha
    Lee, Kyung-Hun
    Song, Jin-Ho
    Jang, Won Il
    Kim, Tae Hyun
    Salvestrini, Viola
    Meattini, Icro
    Livi, Lorenzo
    Shin, Kyung Hwan
    RADIOTHERAPY AND ONCOLOGY, 2024, 199
  • [39] Efficacy of T-DM1 in patients with HER2-positive metastatic breast cancer previously treated with pertuzumab
    Matsui, K.
    Yoshikawa, A.
    Oyama, K.
    Nozaki, Z.
    Tanada, Y.
    Earashi, M.
    Kiyohara, K.
    Nagata, T.
    Fukushima, W.
    Shimizu, T.
    Maeda, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [40] HER2-positive PDX model of breast cancer brain metastasis obtained from patient prior to T-DM1 therapy
    Nielsen, Carsten H.
    Wick, Michael J.
    Gamez, Lizette
    Knudsen, Camilla S.
    Jense, Mette M.
    Rundle, Melissa
    Papadopoulos, Kyriakos P.
    Kjaer, Andreas
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
12345